Pooled Bone Marrow MSC Bank for Consistent Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing clinical protocols for mesenchymal stromal cell (MSC) preparations from single donors exhibit significant donor-to-donor variability and heterogeneity, making it challenging to produce consistent, clinically effective MSC products with predictable proliferation and immunosuppressive potential.
Innovation Solution
A three-step process involving the isolation and pooling of bone marrow mononuclear cells (BM-MNCs) from multiple genetically distinct donors, followed by cryopreservation and serum-free expansion, to create a stable, clinical-grade MSC preparation with enhanced allosuppressive potential and consistent proliferative capability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If MSCs are prepared from single bone marrow donors, then the isolation process is simple, but the preparations exhibit significant donor-to-donor variability and heterogeneity
Solution Approach 1:
The patent combines MSCs from multiple unrelated bone marrow donors into a single pooled preparation. This merging approach eliminates donor-to-donor variability by creating a homogeneous mixture where individual donor characteristics are diluted, resulting in consistent immunosuppressive potential and proliferative capability across different batches.
Solution Approach 2:
The patent changes the fundamental parameter of donor composition from single-donor to multi-donor pooled cells. This parameter change transforms the source material characteristics, ensuring that the final MSC preparation has standardized immunological properties regardless of individual donor variations.
2Reliability
If MSCs are prepared from multiple donors, then the immunosuppressive potential is increased, but the production process becomes more complex
Solution Approach 1:
The patent performs preliminary pooling of mononuclear cells from multiple donors before MSC isolation and expansion. By combining the cellular material in advance, the method simplifies subsequent processing steps while ensuring the final preparation has enhanced and consistent immunosuppressive properties.
Solution Approach 2:
The patent segments the production process into distinct phases: (1) collection and pooling of mononuclear cells from multiple donors, (2) isolation of MSCs from the pooled material, and (3) expansion of the isolated MSCs. This segmentation allows each step to be optimized independently while maintaining overall process efficiency.
3Productivity
If MSCs are expanded in serum-containing medium, then the cell growth is rapid, but the batch-to-batch variability increases
Solution Approach 1:
The patent changes the culture medium composition from serum-containing to serum-free formulation. This parameter change eliminates batch-to-batch variability associated with serum products while maintaining adequate cell expansion rates, thereby improving manufacturing precision without completely sacrificing productivity.
Data Source
AI summary
The present invention pertains to an improved mesenchymal stromal cell (MSC) preparation and a method for producing the same. The invention provides a new strategy to isolate MSC from bone marrow mononuclear cells (BM-MNCs) by pooling BM-MNCs of multiple unrelated (third-party) bone marrow donors. The MSC preparation manufactured in accordance with the methodology of the invention is characterized by a stable proliferative capability and an increased immunosuppressive potential when compared to individual donor MSC preparations or a pool of individual MSCs generated from multiple donors. The MSCs prepared according to the invention are particularly useful for medical applications such as the treatment of graft-versus-host disease (GvHD) in recipients with hematopoietic stem cell transplants, patients with autoimmune disorders and as a cell-based therapy in regenerative medicine.